Literature DB >> 24472023

Paired analysis of plasma proteins and coagulant capacity after treatment with three methods of pathogen reduction.

José Coene1, Katrien Devreese, Bea Sabot, Hendrik B Feys, Philippe Vandekerckhove, Veerle Compernolle.   

Abstract

BACKGROUND: The effect of photochemical pathogen reduction (PR) methods on plasma quality has been the subject of several reports but solid comparative data for the different technologies are lacking. STUDY DESIGN AND METHODS: Plasma (n = 24) photoinactivated with methylene blue (MB), riboflavin (RF), or amotosalen (AS) was compared using a pool-and-split design. Samples were taken before and after treatment with each method and tested for coagulation factors (fibrinogen, Factor [F] II, FV, FVIII, F IX, FXI), natural coagulation inhibitors (Protein C [PC], protein S [PS], antithrombin III [AT]), prothrombin time (PT), activated partial thromboplastin time (APTT), and thrombin generation (TG). The three methods were mutually compared by repeated-measures analysis of variance.
RESULTS: All three PR methods cause significant reduction (p < 0.01) of activity of the procoagulant proteins fibrinogen, FII, FV, FVIII, F IX, and FXI. Coagulation is also affected, with significant changes in PT, APTT, and TG. RF treatment causes a significantly higher decrease in concentration of coagulation factors, PS, and AT than the other methods (p < 0.01). PT, APTT, and TG are also affected most by RF treatment. FII, FVIII, F IX, PC, AT, and PT are best preserved with the MB method and FV, FXI, and TG after AS treatment (p < 0.01). Coagulation factor loss due to the volume loss during PR treatment is more important for MB and AS than for RF.
CONCLUSION: PR treatment of plasma affects coagulation proteins and coagulant capacity. For the RF method this effect is most pronounced, although to some extent compensated by a smaller volume loss.
© 2013 American Association of Blood Banks.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24472023     DOI: 10.1111/trf.12460

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  4 in total

1.  The effect of pathogen inactivation on cryoprecipitate: a functional and quantitative evaluation.

Authors:  Reed W Kamyszek; Matthew W Foster; Brooke A Evans; Keaton Stoner; Jessica Poisson; Amudan J Srinivasan; J Will Thompson; M Arthur Moseley; Micah J Mooberry; Ian J Welsby
Journal:  Blood Transfus       Date:  2020-08-06       Impact factor: 3.443

2.  Pathogen reduction of blood components during outbreaks of infectious diseases in the European Union: an expert opinion from the European Centre for Disease Prevention and Control consultation meeting.

Authors:  Dragoslav Domanović; Ines Ushiro-Lumb; Veerle Compernolle; Sergio Brusin; Markus Funk; Pierre Gallian; Jørgen Georgsen; Mart Janssen; Teresa Jimenez-Marco; Folke Knutson; Giancarlo M Liumbruno; Polonca Mali; Giuseppe Marano; Yuyun Maryuningsih; Christoph Niederhauser; Constantina Politis; Simonetta Pupella; Guy Rautmann; Karmin Saadat; Imad Sandid; Ana P Sousa; Stefania Vaglio; Claudio Velati; Nicole Verdun; Miguel Vesga; Paolo Rebulla
Journal:  Blood Transfus       Date:  2019-12-11       Impact factor: 3.443

3.  Thrombin generation, ProC(®)Global, prothrombin time and activated partial thromboplastin time in thawed plasma stored for seven days and after methylene blue/light pathogen inactivation.

Authors:  Thomas Thiele; Gregor Hron; Sarah Kellner; Christina Wasner; Antje Westphal; Theodore E Warkentin; Andreas Greinacher; Kathleen Selleng
Journal:  Blood Transfus       Date:  2015-07-09       Impact factor: 3.443

4.  Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (Commentary, p. 3026).

Authors:  Chintamani Atreya; Simone Glynn; Michael Busch; Steve Kleinman; Edward Snyder; Sara Rutter; James AuBuchon; Willy Flegel; David Reeve; Dana Devine; Claudia Cohn; Brian Custer; Raymond Goodrich; Richard J Benjamin; Anna Razatos; Jose Cancelas; Stephen Wagner; Michelle Maclean; Monique Gelderman; Andrew Cap; Paul Ness
Journal:  Transfusion       Date:  2019-05-29       Impact factor: 3.157

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.